Poorly Differentiated Neuroendocrine Carcinomas
specificInvasive urothelial carcinoma that lacks the morphological features indicating urothelial origin. Immunohistochemical studies are required to demonstrate the urothelial lineage in these tumors.
7
Centers
0
Active Trials
—
Cancer Funding
Top Centers for Poorly Differentiated Neuroendocrine Carcinomas(7)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive | 57.1 |
| 2 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive | 57.1 |
| 3 | UPMC Hillman Cancer CenterPittsburgh, PA NCI Comprehensive | 57.1 |
| 4 | Moffitt Cancer CenterTampa, FL NCI Comprehensive | 57.1 |
| 5 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive | 57.1 |
| 6 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical | 57.1 |
| 7 | Boston University Cancer CenterBoston, MA | 57.1 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →